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Abstract 
The coronary artery calcification score and pericardial fat volume have recently been reported to be strongly associated with the severity 
and presence of coronary atherosclerosis. However, no studies have explored the outcome of phased progression of atherosclerosis by 
non-contrast computed tomography in asymptomatic people in China. The population-based cohort study in outcome of phased progression 
of atherosclerosis in China (PERSUADE), an observational, longitudinal and prospective cohort study in a target population of healthy sub-
jects based in Jidong Oilfield (China), prospectively analyzes the outcome of phased progression of atherosclerosis by non-contrast computed 
tomography in healthy population. The results of this study are expected to be of value for utilizing noninvasive imaging combine with tradi-
tional cardiovascular risk factors to create a risk stratification and find pertinent biomarkers associated with the outcome of phased progres-
sion of atherosclerosis in healthy people, thereby could help to establish a more personalized treatment of clinical practice. 
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1  Background  
Atherosclerosis is the underlying cause of most cardio-
vascular diseases and the leading cause of death and disabil-
ity world wide. Currently, it has been illustrated that athero-
sclerosis starts with fatty streaks formation and progresses 
with atherosclerotic plaque formation. Previous studies also 
demonstrated that hypercholesterolemia, hypertension, dia-
betes, and dysfunction of endothelium are the common fa-
cilitating factors for atherosclerosis.[1,2] However, there are 
substantial differences in its incidence, prevalence and mor-
tality across countries and ethnicities. Morbidity and mortal-
ity of cardiovascular disease have decreased significantly in 
developed countries, but continue to rise in developing 
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countries.[3] The changes in lifestyle and diet have lead to an 
increase of life expectancy, but also of the burden of car-
diovascular disease and other chronic diseases.[4] Develop-
ing efficient preventive approaches for atherosclerosis pro-
gression may be an effective strategy to minimize the risk of 
cardiovascular events among general populations. Early 
detection may lead to optimum therapeutic intervention. 
Noninvasive measurement of the subclinical atherosclerotic 
burden in asymptomatic people has the potential to improve 
assessment of cardiovascular risk and might contribute to a 
more effective prevention of cardiovascular events. 
Recently, the discovery that pericardial fat may locally 
affect coronary arterial through generation of inflammatory 
cytokines.[5] Moreover, coronary artery calcification has 
been strongly recommended to be added as one of the risk 
factors for predicting adverse cardiovascular events.[6] In 
terms of technology, non-contrast chest computed tomo-
graphy (NCT) can be routinely performed to detect pericar-
dial fat volume (PFV) and measure coronary artery calcifi-
cation score (CACS).[7,8] Given the high prevalence of 
atherosclerosis, studying risk factors or characteristics for 
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atherosclerosis in Chinese population will have greater pub-
lic health and clinical implications.  
A growing body of evidence reveals that cardiac fat de-
posits maybe associated with multiple metabolic risk factors, 
such as hypertension, hyperlipidaemia and diabetes, with an 
unfavorable cardiometabolic risk profile suggesting that a 
high pericardial fat accumulation might play a major role in 
the pathogenesis of coronary atherosclerosis disease(CAD), 
and as a new biomarker for cardiovascular risk assessment.[9] 
Previous researches have reported CACS had correlation 
with PFV, but no correlation with body mass index (BMI) 
and blood lipid levels. Therefore, PFV may have a unique 
role in coronary artery calcification even in atherosclerosis 
progression. Nakanishi R, et al. demonstrated that increase 
in epicardial fat volume is associated with greater CACS 
progression in subjects at intermediate risk by coronary cal-
cification score.[10] Contrary to the previous reports, Wassel, 
et al.[11] studied the relationship between the PFV and the 
coronary calcium score in 600 patients using chest com-
puted tomography (CT) scans at two time points with an 
interval of about four years, and found that PFV is not asso-
ciated with the presence, severity and progression of coro-
nary artery calcium. However, there is no comprehensive 
evaluation of the effects of CACS, PFV and cardiovascular 
events in China. 
2  Objective 
Our main aim is to spread the noninvasive imaging and 
proper biomarker associated with the outcome of phased 
progression of atherosclerosis in healthy people. Baseline 
examination consists of screening for CACS and measure-
ment of PFV by non-contrast chest computed tomography, 
as well blood sampling for determination of traditional risk 
factors will be collected. Moreover, follow-up at annual 
year will include a repetition of baseline measurements and 
cardiovascular events. 
3  Methods 
3.1  Study design and population cohort 
The PERSUADE study is an observational, longitudinal, 
prospective cohort study that will include 3000 asympto-
matic participants of Jidong Oilfield community for a total 
of 10 years of follow-up (Figure 1). The community is geo-
graphically located in Tangshan City in northern China and 
is mainly comprised of employees of the Jidong Oilfield and 
their family members. From April 2014, all residents aged 
40 to 75 years were invited to participate in our study at the  
 
Figure 1.  Flowchart of PERSUADE study. 
time of their regular annual check up performed by the Ji-
dong Staff Hospital. 
The following are the exclusion criteria: (1) prior history 
of cardiovascular disease (including myocardial infarction, 
angina pectoris, stroke, peripheral vascular disease, aortic 
aneurysm, angioplasty, heart surgery, atrial fibrillation, 
heart failure, heart valvular diseases or any other heart dis-
ease); (2) active treatment for cancer, history of transplant 
with active immunosuppressive or immunomodulator 
treatment; (3) morbid obesity (body mass index ≥ 40 kg/m2), 
chronic kidney disease (glomerular filtration rate < 60 
mL/min per square meter), presence of any disease that de-
creases life expectancy to < 5 years, or any condition that 
could affect adherence to the study procedures; (4) partici-
pants are also excluded if they were pregnant or lactating.   
3.2  Data collection 
All data is obtained at the annual medical exam that the 
Jidong Oilfield provides to all workers and their family. The 
clinical exam follows standardized protocols using validated 
procedures and instruments. Data collection at the annual 
medical exams is conducted by the physicians and nurses of 
the Jidong Staff Hospital, who undergo training and stan-
dardization programs organized by the study investigators. 
Basic demographic information of all participants is col-
lected by trained doctors using validated questionnaire spe-
cifically designed for this study. 
3.3  Assessment of demographic variables and cardio-
vascular risk factors 
Detailed information on demographic variables (e.g, age, 
gender, household income, level of education, and previous 
history of diseases) are collected. The average monthly in-
come is categorized as “< ¥ 3,000”, “¥ 3,000–4,999” and “ 
¥ 5,000”. The level of education is categorized as “illiteracy 
or compulsory education”, “high school” or “College/Uni-
versity”. The smoking status is classified as “never”, “for-
mer”, or “current” according to self-reported information. 
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Body weight (kg) and body height (cm) are measured, and 
the body mass index is calculated as body weight (kg) di-
vided by the square of height (m2). Hypertension is defined 
based on the following information alone or in combination: 
(1) as presence of a history of arterial hypertension; (2) us-
ing antihypertensive medication; or (3) a systolic blood 
pressure > 140 mmHg or a diastolic blood pressure > 90 
mmHg. Diabetes mellitus is defined as a self-reported his-
tory, current treatment with insulin, oral hypoglycemic 
agents or fasting blood glucose level > 126 mg/dL. Dyslipi-
demia is defined by a self-reported history, current use of 
cholesterol lowering medicine, a total cholesterol level > 
220 mg/dL or triglyceride > 150 mg/dL or low density lipo-
protein > 160 mg/dL. 
3.4  Laboratory analysis  
At each examination, blood samples are collected from 
the antecubital vein in the morning under fasting conditions. 
They will be stored in vacuum tubes containing Ethylene 
Diamine Tetraacetic Acid (EDTA). Fasting blood glucose 
will be measured with the hexokinase/glucose-6-phosphate 
dehydrogenase method. Cholesterol and triglyceride con-
centration will be measured enzymatically [inter-assay coef-
ficient of variation: < 10% (Mind Bioengineering Co. Ltd, 
Shanghai, China)]. For all participants, serum creatinine, 
cholesterol, low-density lipoproteins (LDL-C), triglycerides 
as well as glucose levels will be assessed.  
3.5  Analysis of CACS and PFV 
As part of the protocol, all participants will undergo NCT 
for quantification of CACS and PFV. The NCT is acquired 
using a 64-slice CT scanner (Siemens Dual Source 64-Slice 
Definition, Forchheim, Germany). For scanning, a standard 
non-contrast prospective scan will be performed. Acquired 
images will be then transferred to a research workstation for 
quantification of CACS and PFV. All CT images will be 
initially reviewed by two experienced CT analysts using 
semiautomatic, commercially available software (synoMul-
tiModality Workplace, syngoMMWP VW 40A). 
CACS is defined as a focus of at least four contiguous 
pixels with a CT density of > 130 Hounsfield units (HU) 
and quantified using the Agatston method. Total Agatston 
CACS is calculated as the sum of calcified plaque scores of 
all coronary arteries. Pericardial fat includes all adipose 
tissue enclosed by the visceral pericardium, involving all fat 
directly surrounding the coronary arteries. Image data will 
be processed as following. First, the upper slice limit 
marked by bifurcation of the pulmonary trunk, and lower 
slice limit identified as the last slice containing any portion 
of the heart, are manually chosen by an expert reader 
blinded to patient status and clinical NCT interpretation. 
Next, the reader defines five to seven control points on the 
pericardium in each transverse view. The PFV is then 
automatically calculated (reported in cm3). Contiguous 
3-dimensional voxels between the HU limits of –195 to –45 
are defined as fat voxels.  
3.6  Follow up and outcome assessment 
Participants will be followed up by face-to-face inter-
views every year in a routine medical examination. Data on 
clinical outcomes will be collected through a standard op-
erational procedure follow up system. The follow up system 
involves linkage of the study database to files from general 
practitioners, medical specialists and discharge reports in 
case of hospitalization. With respect to the vital status of 
participants, the information is also obtained regularly from 
the municipal health authorities in Tangshan city. After no-
tification, cause and circumstances of death will be diag-
nosed by general practitioners using questionnaire. 
The disease diagnosis will be confirmed only after re-
view of the medical records by an End Points Committee of 
physicians that includes a cardiologist, neurologist, cancer 
experts, etc. The End Points Committee of physicians in-
cluding membership, role and responsibilities will be ap-
proved before the start of the study by the executive com-
mittee. Primary endpoints are major adverse cardiovascular 
events (MACE) including cardiac death, myocardial infarc-
tion, stroke and revascularization. In brief, questionnaires on 
the current state of health including questions about current 
medications, hospital admissions, and outpatient diagnosis 
of cardiovascular disease are annually sent to the partici-
pants. In parallel, all death certificates are regularly screened. 
Incident cardiovascular morbidity and fatal events will be 
validated by reviewing hospital records and records of the 
attending physicians, and classified by an external endpoint 
committee, blinded to the risk factor status and the CACS.  
3.7  Statistical analyses  
The data management system including the statistical 
analysis is performed using the SAS software (version 9.4; 
SAS Institute, Cary, North Carolina, USA). Firstly, the dis-
tributions (mean ± SD) of the parameters are calculated. 
Normal distribution of the parameters is assessed using the 
Kolmogorov-Smirnoff test. Secondly, the parameters are 
compared between the groups, using either the student’s t 
test for paired or non-paired samples of normally distributed 
parameters or the Wilcoxon-Mann-Whitney test or the 
Wilcoxon test for non-parametric variables. The Chi- 
squared test is applied for the comparison of categorical 
variables. Thirdly, multivariate associations between the 
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various parameters are performed using multivariable re-
gression analyses or binary regression analyses. Fourthly, a 
longitudinal assessment of associations and a survival 
analysis for the combination of major vascular events and 
for each vascular event will be performed using the Kap-
lan-Meier curves in relation to PFV. Cox multivariate re-
gression models will be used to compare the probability of 
having a vascular event in the follow-up cohorts, adjusting 
for the possible confounders. The hazards ratios (HR) will 
be presented with their corresponding 95% confidence in-
tervals (CI). The level for statistical significance will be set 
at α = 0.05 (two-tailed). 
3.8  Ethics statement 
The study protocol is complied with the World Medical 
Association Declaration of Helsinki and China’s regulations 
and guidelines on good clinical practice. Ethical clearance 
for the trial has obtained from the Ethical Committee of the 
Jidong Staff Hospital. Informed consents will be obtained 
from all participants before recruiting into the study. 
4  Discussion 
The PERSUADE study will prospectively evaluate the 
relation between non-invasive CT imaging based risk fac-
tors and phased progression of atherosclerosis in asympto-
matic population in China. In a planned long-term follow up, 
data from clinical parameters, laboratory tests, CACS, PFV 
and the occurrence of cardiovascular events will be col-
lected longitudinally to build up a predicting model for the 
risk of atherosclerosis progression. 
Atherosclerosis is a long-term condition that progresses 
over many decades. It usually produces no symptoms until 
that arterial narrowing significantly reduces blood supply to 
an organ. So early intervention and preventive strategies 
have become major targets for predictive, preventive and 
personalized medical studies. Previous hospital-based stud-
ies have indicated relationship between traditional cardio-
vascular risk factors and atherosclerosis progression.[12–16] 
For example, participants from the cohort of the Korean 
Atherosclerosis Study 2 (n = 402, mean age of 54 years, 
57.0% men) underwent 64-slice multi-detector row com-
puted tomography (MDCT) to assess pericardial fat amount, 
CACS, severity of coronary artery stenosis, and plaque 
characteristics. Patients with atherosclerotic lesion had sig-
nificantly larger volume of pericardial fat than patients 
without atherosclerosis (308 ± 96  cm3 vs. 251 ± 93 cm3; P 
< 0.01).[7] Our study is a population based survey, and the 
participants underwent NCT for CACS and PFV measure-
ment every year to evaluate the atherosclerosis risk factors. 
In this study, we had focus on the CACS and PFV by 
NCT. NCT screening requires no preparation and avoids the 
use of intravenous contrast. This technique can be operated 
in any participants able to lay flat and perform a single 
breath hold. The participant is exposed to a low dose of ra-
diation less than 1 mSv, akin to mammography and less 
than annual exposure from natural sources(3–4 mSv). To 
date, CACS has been applied to more than 100,000 partici-
pants, including multiple large prospective studies with up 
to 10-year follow up.[17,18] Across these studies, CACS has 
demonstrated a consistent ability to assess cardiovascular 
risk in asymptomatic patients beyond that provided by al-
ternative noninvasive tests and risk calculators. In a subset 
of participants in the cardiovascular health study, CACS and 
intima-media thickness (IMT) seemed to predict CVD 
events in a similar manner, but IMT outperformed CACS 
for stroke prediction.[19] 
It has been postulated that paracrine effects of pericardial 
fat may be a potent determinant of coronary plaque devel-
opment and progression. Pericardial fat, owing to the ana-
tomical proximity with coronary arteries and heart, has been 
found to contain higher levels of inflammatory markers and 
adipokines that can locally accelerate the atherosclerotic 
process by endothelial dysfunction, local proliferation of 
smooth muscle cells and increased plaque instability 
through apoptosis and neovascularization.[20, 21] PFV incre-
ment has been observed to have a strong association with 
various inflammatory marker changes and early coronary 
endothelial dysfunction that may precede coronary calcifica-
tion and the development of mature atherosclerotic changes. 
The present study has several strengths, including its 
large sample size, the stability and low mobility may facili-
tate longtime follow up examinations. Moreover, our NCT 
is noninvasive examination and radiation dose is very low. 
Nevertheless, several limitations of this study should be 
considered. Firstly, this is a single-centre investigation, and 
the participants are in the northern of China, so it couldn’t 
completely stand for whole Chinese population. Secondly, 
our measuring method for quantifying PFV is semi-auto-
matic and we cannot accurately measure the epicardial fat 
volume by non-contrast methods. Thirdly, because of the 
non contrast, we can not obtain the condition of coronary 
artery stenosis. 
In brief, the PERSUADE study is expected to analyze the 
clinical characteristics of asymptomatic people and to set up 
risk stratification model by collecting the cardiac CT imag-
ing and risk factors. Combining with follow up of cardio-
vascular events, the present study may help to achieve early 
detection, early prevention of the cardiovascular disease and 
establish a more personalized treatment of clinical practice. 
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5  The study status 
This program began in April 2014 and patients’ follow 
up visit is ongoing now. The baseline clinical information 
was collection and exam data will be transfer and arrange 
into our database every year then. 
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